[EN] REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS [FR] AGONISTES REV-ERB POUR DES TROUBLES INFLAMMATOIRES À MÉDIATION PAR TH17
摘要:
The present disclosure provides compounds and their pharmaceutical compositions as selective agonists of REV-ERBα. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.